Navigation Links
QIAGEN and Exosome Diagnostics to Develop First-In-Class, Non-Invasive Diagnostics for Key Genetic Biomarkers in Lung and Other Cancers
Date:1/13/2014

GERMANTOWN, Maryland, and HILDEN, Germany, January 13, 2014 /PRNewswire/ --


  • Expanding collaboration to develop FDA-regulated diagnostics based on exosomes to measure gene mutations targeted by new anti-cancer therapies
  • Non-invasive detection of biomarkers from blood reduces patient risk and advances access to the benefits of personalized medicine
  • Automated biofluid-based molecular diagnostics have significant potential to replace many costly and invasive tissue biopsies and add new testing options
  • QIAGEN set to launch during 2014 the first in a series of new sample preparation kits for processing nucleic acids from biofluid exosomes

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced an expansion of its strategic partnership with Exosome Diagnostics Inc. to develop a first-in-class, non-invasive molecular in-vitro diagnostics for use in diagnosing and monitoring patients. The novel blood based diagnostic detects certain mutations of an undisclosed gene associated with non-small cell lung cancer (NSCLC) and other malignancies and has the potential to be paired with several new anticancer therapeutics. QIAGEN will have worldwide exclusive rights for commercialization and intends to submit the test to the U.S. Food and Drug Administration (FDA) following clinical validation. Financial terms were not disclosed.

Exosomes are the messenger packages in a fundamental biological communication system that transmits genetic instructions from cell to cell. The technology developed by Exosome Diagnostics allows non-invasive detection of key disease associated gene mutations and gene expressions in blood, urine and cerebrospinal fluid without the need for a risky and burdensome surgical tissue biopsy. The
'/>"/>

SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Maverix Biomics Forms Strategic Co-Marketing Alliance with QIAGEN
2. QIAGEN Offers Clinical Labs Early Access to New Ingenuity Solution for Streamlined Interpretation of Patient Sequencing Data
3. Financial Results, Appointments, Earnings Conferences, and Partnerships - Research Report on New Oriental Education & Technology, Acacia Research, DeVry, Capella Education, and Qiagen NV
4. Exosome Diagnostics and QIAGEN Partner to Launch Comprehensive Line of Biofluid Nucleic Acid Kits to Address Limitations of Tissue Biopsy in Clinical Research Market
5. QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities
6. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
7. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
8. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
9. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
10. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
11. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional is ... and tissue for a wide range of away ... its product lines in healthcare, including hospitals, long-term ... Professional is introducing its healthcare products and solutions ... understands the importance of infection control in the ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014 /PRNewswire/ ... of U.S. patient-level claims data, anemic chronic kidney ... with their erythropoiesis-stimulating agent (ESA) medication. In addition, ... Janssen,s Procrit. Other key findings ... in Nephrology: An Analysis of Erythropoiesis Stimulating Agents ...
(Date:9/30/2014)... 30, 2014   Acutus Medical, Inc. ... real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping ... or sustain complex cardiac arrhythmias, including atrial fibrillation, announced ... developing its imaging/mapping system as well as bring to ... Acutus Medical to complete work on the AcQMap TM ...
Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... Inc. (OTCBB: PLCSF), a company focused on innovative medical ... REMEDIAL II investigator-sponsored clinical trial of RenalGuard® ... , a peer-reviewed journal of the American Heart Association ... in the September 2011 issue of the publication.  The ...
... A national analysis conducted by Sperling,s BestPlaces and ... Columbus, Ohio, as one of the nation,s Hypertension ... factors and complications. The identification of the Hypertension ... hypertension awareness program called Commit to Control ...
Cached Medicine Technology:REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 2REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 3REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 4Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 2Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 3Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 4
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth ... new medical specialty practice through a unique partnership with ... be located within the company’s Shrewsbury location and will ... Tawfik of American Heart Center, P.C., a highly regarded ... offer Integrated Medicine Alliance patients top notch cardiovascular care ...
(Date:9/30/2014)... 30, 2014(BRONX, NY)Medications are the leading cause of allergy-related ... of death certificates from 1999 to 2010, conducted by ... Albert Einstein College of Medicine of Yeshiva University ... Journal of Allergy and Clinical Immunology , also found ... particularly high among older people and African-Americans and that ...
(Date:9/30/2014)... 2014 EverStryke , the permanent match ... SurvivalLife.com along with a free book and class all about ... Michaels, prompting an investigative review. , “Joe Marshall of ... survival and preparation niche, and this product is an excellent ... and survival products that Joe offers on his website to ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... option to help diabetics curb their sweet tooth, but ... Nature this September, suggests that zero-calorie sweeteners may ... 2 diabetes. , The Weizmann Institute of Science ... fed artificial sweeteners to mice, the mice developed glucose ...
(Date:9/30/2014)... 30, 2014 Hospice & Palliative ... “In Celebration” gala, honoring three outstanding individuals for ... striving to provide extraordinary and dignified comfort, care ... serious or life-limiting illness. , The event was ... NY and recognized William (Bill) J. McGuinness, Director ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2
... President of ... the Lyme Disease Association., JACKSON, N.J., Oct. 4 The ... "A Clinical Appraisal,of ,Chronic Lyme Disease.," Eleven of its authors also ... by the,Connecticut Attorney General for the development of those Guidelines.,Although the ...
... to stress the disease,s link to heart disease , , THURSDAY, Oct. ... pretty. , An acclaimed rock musician and record producer, he was ... Fox television,s soon-to-be monster hit American Idol . , Then ... diabetes. , Today, with his disease under control, Jackson wants to ...
... technological know how to patient care were demonstrated by ... , Imperials Rector, Sir Richard Sykes, and Professor of ... Darzi, took the PM on a tour of the ... The Institute is at the forefront of medical innovation, ...
... Nastech Pharmaceutical,Company Inc. (Nasdaq: NSTK ) ... to Chief Scientific Officer of Delivery. Dr. Costantino,will ... new,drug delivery technologies for peptide and protein therapeutics. ... is retiring,tomorrow, October 5, 2007, as was previously ...
... Oct. 4 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM: TSX-V) ... the American,College of Surgeons 93rd Annual Clinical Congress ... CRH will be focused on recruiting General ... its number of Centers for,Colorectal Health. Commenting ...
... Series, new rules for the first time forced players to ... and coaches had to strategize how pitchers were used more ... 12 and under could throw up to six innings per ... an increase in reported cases of young pitchers experiencing arm ...
Cached Medicine News:Health News:NEJM Owes Patients Responsible Journalism, Says Lyme Disease Association 2Health News:Randy Jackson Takes Aim at Diabetes 2Health News:Randy Jackson Takes Aim at Diabetes 3Health News:Prime Minister views innovative health technology at Imperial College London 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 3Health News:CRH Medical to exhibit at American College of Surgeons Annual Clinical Congress 2Health News:How pitching changes little leaguers' shoulders 2Health News:How pitching changes little leaguers' shoulders 3
... 2 60-ms bursts of 50 Hz separated by .75 ... Tetanus: 50 Hz (50 pulses/s) or 100 Hz (100 ... Output Current: Adjustable from 0-70 mA , Stimulus ... Battery LED (green) indicates that the units on; it ...
Anesthesia Associates Nerve Stimulator Model AA 1050...
... newest peripheral nerve stimulator from B. Braun Medical. ... providing advanced digital technology. , ,Your ability ... allows the localization of practically all mixed nerves ... ,An additional optional component for the HNS11 is ...
... original MS-III design the new ... keypad and battery ... MS-IV peripheral nerve stimulator can ... in operating room, post anesthesia ...
Medicine Products: